Comparison of survival outcomes between squamous cell carcinoma and adenocarcinoma/adenosquamous carcinoma of the cervix after radical radiotherapy and chemotherapy

Ping Liu1†, Mei Ji2†, Yanxiang Kong3†, Zhifeng Huo1†, Qiubo Lv4, Qinghuang Xie5, Danbo Wang6, Biliang Chen7, Hailin Wang8, Zhumei Cui9, Qianqing Wang10, Xiaonong Bin11, Jinghe Lang1,12 and Chunlin Chen1*

Abstract

Background: This study aimed to compare the survival outcomes between squamous cell carcinoma (SCC) and adenocarcinoma/adenosquamous carcinoma (AC/ASC) of the cervix after radical radiotherapy and chemotherapy.

Methods: Propensity score matching (1:4) was used to compare overall survival (OS) and disease-free survival (DFS) in cervical cancer patients with SCC and AC/ASC in China.

Results: Five thousand four hundred sixty-six patients were enrolled according to the criteria. The 5-year OS and DFS in the SCC group ($n=5251$) were higher than those in the AC/ASC group ($n=215$). After PSM (1:4), the 5-year OS and DFS in the SCC group were higher than those in the AC/ASC group (72.2% vs 56.9%, $p<0.001$, HR = 1.895; 67.6% vs 47.8%, $p<0.001$, HR = 2.056). In stage I-IIA2 patients, after PSM (1:4), there was no significant difference in 5-year OS between the SCC group ($n=143$) and the AC/ASC group ($n=34$) (68.5% vs 67.8%, $P=0.175$). However, the 5-year DFS in the SCC group was higher than that in the AC/ASC group (71.0% vs 55.7%, $P=0.045$; HR = 2.037, $P=0.033$). In stage IIB-IV patients, after PSM (1:4), the 5-year OS and DFS in the SCC group ($n=690$) were higher than those in the AC/ASC group ($n=173$) (70.7% vs 54.3%, $P<0.001$ vs 1.940% vs 45.8%, $P<0.001$).

Conclusions: For stage I-IIA2, there was no significant difference in 5-year survival time, but patients with AC/ASC were more likely to relapse. In the more advanced IIB-IV stage, the oncological outcome of radical radiotherapy and chemotherapy of cervical AC/ASC was worse than that of SCC.

Keywords: Cervical cancer, Squamous cell carcinoma, Adenocarcinoma, Adenosquamous carcinoma, Radiochemotherapy, Overall survival, Disease-free survival

Background

Cervical cancer is the fourth leading cause of cancer death among women worldwide. Squamous cell carcinoma (SCC) is the most common pathological type, followed by adenocarcinoma and adenosquamous carcinoma (AC/ASC). In 2018, there were 13,240 new cases in the United States, with 4170 deaths [1]. SCC accounts for...
approximately 70% of cervical cancer, and AC accounts for approximately 20% [2]. In our Chinese cervical cancer diagnosis and treatment database, there were 63,926 cases of cervical cancer from 2004 to 2018, including 56,141 cases of SCC (87.82%) and 5414 cases of AC/ASC (8.47%).

The current NCCN guidelines recommend referring to SCC for the clinical treatment of AC [3], but whether there is a difference in survival outcome between cervical AC/ASC and SCC has been controversial. Most studies suggest that the overall survival rate of patients with early cervical AC/ASC after surgical treatment is lower than that of patients with SCC [4–6], while some think that the survival rates is similar [7, 8]. The oncological outcome of patients with cervical SCC and AC/ASC after radical radiotherapy and chemotherapy is controversial at present. A study based on the National Cancer Database of Korea shows that the survival rate of patients with cervical AC is lower than that of patients with SCC [9]. Other studies also suggest that the oncological outcome of patients with cervical AC/ASC is worse than that of patients with SCC [10–12]. However, Rose PG et al. [13] thought that the prognosis of AC/ASC after simultaneous radiotherapy and chemotherapy was similar to that of SCC, and Katanyoo K et al. [14] thought that the pathological type did not affect the survival outcome.

Therefore, for cervical cancer patients receiving radical radiotherapy and chemotherapy, the prognostic significance of SCC and AC/ASC is worthy of further study, and the above studies lack data from developing countries. China has a large amount of clinical data on cervical cancer, which has important reference value. We combined the Chinese mainland with 37 hospitals that can independently carry out surgical treatment of cervical cancer to conduct a real-world study (RWS) to build a large database on the clinical diagnosis and treatment of cervical cancer in China. Among them, there were 11,433 cases of radical radiotherapy and chemotherapy from 2004 to 2018 and 10,426 cases of SCC (91.19%). AC/ASC accounted for 521 cases (4.56%). The purpose of this study was to further explore the oncological outcome of radical radiotherapy and chemotherapy for cervical SCC and AC/ASC with the help of this large database.

**Methods**

**Collection, management, follow-up and storage of the China Cervical Cancer Clinical Database**

This retrospective cohort study was conducted following the ethical standards adopted in the 1964 Declaration of Helsinki. Clinical diagnosis and treatment for cervical cancer in China (Four C) was approved by the Ethics Committee of the Nanfang Hospital of Southern Medical University (approval number NFEC-2017–135 and clinical trial number CHiCTR1800017778; International Clinical Trials Registry Platform Search Port, http://apps.who.int/trialsearch/). Uniformly trained gynaecologists collected the cervical cancer patients’ general data, disease-related examination results, adjuvant treatment data and follow-up data from 2004 to 2018. The clinical staging from 2004 to 2009 were revised according to the 2009 FIGO guidelines while cases in 2018 were staged according to FIGO 2018 [15–20].

Trained gynaecologists and monitored by specified staff conducted follow-up phone calls to know the information of patients’ survival, recurrence status, complications and so on. We conducted a thorough search of the outpatient system, picture archiving and communication system (PACS), and clinical laboratory information system for approximately 20% [2]. Inclusion criteria: Age ≥ 18 years old; pathological diagnosis of cervical cancer by biopsy; the histological type was SCC, AC/ASC; FIGO stage I-IV stage; the year of diagnosis was from 2004 to 2018; initial treatment with radiotherapy (RT), concurrent chemoradiotherapy (CCRT) or radiotherapy + chemotherapy; radiation treatment including external irradiation + afterloading; radiotherapy dose higher than 40 Gy; chemotherapy regimens including paclitaxel + carboplatin, paclitaxel + other platinum, platinum + 5FU, platinum + other, etc., used according to guidelines and drug instructions; survival outcome information available; and all patients able to complete the treatment.

Exclusion criteria: Do not meet the above conditions; special types of cervical cancer: histological types other than SCC or AC/ASC, including undifferentiated carcinoma, neuroendocrine carcinoma, sarcoma, lymphoma and other rare histological types; pregnancy complicated with cervical cancer, accidental discovery of cervical cancer, stump cancer or other malignant tumours; radiotherapy regimen unknown.

**Outcome evaluation and statistical analysis**

The primary outcomes were 5 year overall survival (OS) and disease-free survival (DFS). We used SPSS statistical software (version 23.0, SPSS Inc., Chicago, IL, USA) to do the data analysis. Two independent sample t tests were used for continuous variables, and the X2 test or nonparametric test was used for categorical variables or grade variables. In addition, Propensity score matching (1:4) was used according to the patient’s age, FIGO
stage, histological type, and tumour diameter to adjust the baseline data in this study. The log-rank test in the Kaplan–Meier (KM) method were performed to compare the differences in the survival curves. The hazard ratio was calculated only for the variables included in the Cox regression model. \( P < 0.05 \) was considered significant. We invited statistical experts to review all statistical methods and procedures used in this study.

Results

The screening process of data

Among the 63,926 cases collected by Four C, there were 11,433 patients who underwent radiotherapy and chemotherapy, and 5466 of them met the criteria (SCC vs AC/ASC group, 5251 vs 215). After propensity score matching (1:4), the two groups included 843 and 212 cases, respectively. A total of 848 patients who underwent radiotherapy and chemotherapy in stage I-IIA2 were divided into two groups (SCC vs AC/ASC group, 807 vs 41). After propensity score matching (1:4), the two groups included 143 and 38 cases, respectively. A total of 4618 patients who underwent intermediate radiotherapy and chemotherapy were in stage IIB-IV stage (SCC vs AC/ASC group, 4444 vs 174). After propensity score matching (1:4), the two groups included 690 and 178 cases, respectively. The data screening process is shown in Fig. 1.

Differences in survival outcomes between the SCC group and AC/ASC group before and after matching: patients meeting the inclusion criteria

To reduce the influence of confounding factors, we performed propensity score matching (1:4) and then survival analysis for the 5466 patients who met the inclusion criteria. Before matching, the median follow-up times for the SCC group and AC/ASC group were 31 months and 26 months, respectively. The number of deaths within 5 years was 998 (19%) and 68 (31.6%), the 5-year OS was 73.0% vs 57.4% \((P < 0.001)\), and the DFS was 68.0% vs 48.1% \((P < 0.001)\). Cox multivariate analysis showed that the risk of death or recurrence/death was higher in the AC/ASC group \((HR = 1.971, P < 0.001; HR = 2.106, P < 0.001)\).

After matching, the median follow-up period was 31 months and 26 months. The number of deaths within 5 years was 165 (19.57%) and 68 (32.07%), respectively, and the 5-year OS was 72.2% vs 56.9% \((p < 0.001)\). The DFS was 67.6% vs 47.8% \((p < 0.001)\).

Cox multivariate analysis showed that the risk of death or recurrence/death was higher in the AC/ASC group \((HR = 1.895, P < 0.001; HR = 2.054, P < 0.001)\) (Table 1, Fig. 2).

Differences in survival outcomes between the two groups before and after matching: patients with stage I-IIA2 cervical cancer

In stage I-IIA2, the baseline of the SCC group \((n = 807)\) and AC/ASC group \((n = 41)\) was unbalanced. After propensity score matching (1:4), 143 cases and 38 cases were included in each group, and there was no significant difference in survival analysis between the two groups. Before matching, the median follow-up period was 32 months and 27 months. The number of deaths within 5 years was 126 (15.61%) and 9 (21.95%), the 5-year OS was 76.1% vs 70.5% \((P < 0.01)\), and the DFS was 72.8% vs 68.0%...
56.8% \((P=0.015)\). Cox multivariate analysis showed that there was no significant difference in the risk of death between the two groups, but the risk of recurrence/death was higher in the AC/ASC group.

After matching, the median follow-up time was 36 months and 25 months. The number of deaths in the two groups within 5 years was 25 (17.48%) and 9 (23.68%). The 5-year OS of the two groups was 68.5% vs 67.8% \((P=0.075)\), and DFS was 71.0% vs 55.7% \((P=0.045)\). Cox multivariate analysis showed that there was no significant difference in the risk of death between the two groups, but the risk of recurrence/death was higher in the AC/ASC group (Table 2, Fig. 3).

### Differences in survival outcomes between the two groups before and after matching: patients with stage IIB and IV cervical cancer

In stage IIB-IV stage, the baseline was unbalanced between the SCC group \((n=4444)\) and the AC/ASC group \((n=174)\). After propensity score matching (1:4), 690 and 173 patients were included in each group. There was no significant difference in survival analysis between the two groups. Before matching, the median follow-up time was 31 months and 25 months, the number of deaths within 5 years was 872 (19.62%) and 59 (33.90%), the 5-year OS was 72.5% vs 67.1% \((P<0.001)\), and DFS was 67.1% vs 46.1% \((P<0.001)\), respectively. Cox multivariate analysis showed that the risk of death or recurrence/death was higher in the AC/ASC group (HR = 2.019, \(p<0.001\); HR = 2.131, \(P<0.001\)).

After matching, the median follow-up times of the two groups were 31 months and 26 months. The number of deaths within 5 years was 145 (21.01%) and 59 (34.10%). The number of deaths or relapses was 192 (27.81%) and 70 (40.46%), respectively. The 5-year OS was 70.7% vs 54.3% \((P<0.001)\), and DFS was 65.2% vs 45.8% \((P<0.001)\). Cox multivariate analysis showed that the risk of death or recurrence/death was higher in the AC/ASC group (HR = 1.940, \(p<0.001\); HR = 2.057, \(P<0.001\)) (Table 3, Fig. 3).

### Discussion

In recent years, due to the popularity of cervical cancer screening, the global incidence of squamous cell carcinoma (SCC) has decreased significantly, from 90% in 1950–1960 to 75%, while the proportion of adenocarcinoma (AC) has increased year by year, from 5 to 20%–25% [21]. The reason for this phenomenon may be that cytological screening of cervical cancer greatly reduces the incidence of squamous cell carcinoma, while...
adenocarcinoma is mostly endogenous, and most of the lesions are located at the inner mouth of the cervical canal, in which decreases the detection rate of adenocarcinoma by cytological screening [22, 23]. At present, there is no difference in treatment between cervical SCC and adenocarcinoma/adenosquamous carcinoma (AC/ASC), but the clinical features and prognosis of AC are different from those of SCC. Whether patients with different histological subtypes have different survival outcomes is still a controversial topic.

The previous literature has shown that in cases of radical radiotherapy and chemotherapy for cervical cancer, the oncological outcome of AC/ASC is worse than that of SCC. A study based on South Korea’s national cancer incidence database showed that the survival rate of patients with cervical cancer was improved after simultaneous chemotherapy, but the survival rate of patients with AC was still lower than that of patients with SCC [9]. Meanwhile, Huang YT, Yokoi E and Hu K and other researchers founded the prognosis of AC/ASC patients is worse than that of SCC patients [10–12]. The 5-year OS of SCC is 58.6%—85.2%, and the 5-year OS of AC/ASC is 26.7%—75.4%. However, some studies suggest that the oncological outcomes of the two are similar. For example, Rose PG et al. [13] found that the prognosis of AC/ASC after simultaneous radiotherapy and chemotherapy was similar to that of SCC. Katanyoo K et al. [14] thought that the histological type did not affect the survival outcome.

In this study, all cervical cancers were analysed according to the inclusion criteria, and it was found that the oncological outcome of the SCC group was better. After controlling for confounding factors by propensity score matching (1:4), the oncological outcome of the SCC group was still better. The 5-year OS was 72.2% vs 56.9%, $p < 0.001$, HR = 1.895; the DFS was 67.6% vs 47.8%, $p < 0.001$, HR = 2.054. Further analysis according to different stages revealed no significant difference in 5-year OS between the two groups before and after propensity score matching (1:4) in stage I-IIA2, but the 5-year DFS in the SCC group was higher than that in the AC/ASC group (before matching, OS: 76.1% vs 70.5%, $P = 0.170$; DFS: 72.8% vs 56.8%, $P = 0.015$, HR = 1.945, $P = 0.018$; after matching, OS: 68.5% vs 67.8%, $P = 0.175$; DFS: 71.0% vs 55.7%, $P = 0.045$, HR = 2.037, $P = 0.033$). For

**Fig. 2** Survival curves before and after patient matching. *Before matching, panels A and B; after matching, panels C and D. SCC squamous cell carcinoma, AC/ASC adenocarcinoma/adenosquamous carcinoma.
stage IIB-IV, the results both before and after matching suggested that the oncological outcome of the SCC group was better (before matching, OS: 72.5% vs 67.1%, \( p < 0.001 \), HR = 2.019; DFS: 67.1% vs 46.1%, \( p < 0.001 \), HR = 2.131; after matching, OS: 70.7% vs 54.3%, \( P < 0.001 \), HR = 1.940; DFS: 65.2% vs 45.8%, \( P < 0.001 \), HR = 2.057).

The results of this paper are contrary to the results of Rose PG and Katanyoo K [13, 14] and basically consistent with the results of Lee JY, Huang YT, Yokoi E and Hu K [9–12]. The reasons may be as follows: (1) The number of included cases differed across studies. Rose PG and Katanyoo K analysed 1671 cases (SCC 1489, AC/ASC 182) and 423 cases (SCC 282 and AC/ASC 141 cases), respectively, so the difference between groups may not be accurately reflected. However, Lee JY et al. analysed 80,766 cases (SCC 64,531, AC/ASC 7256). The sample size was so large that the result is similar to that in this paper. (2) We performed the Propensity score matching(1:4) while other studies didn’t use such statistical method. Due to the significant difference in baseline characteristics between the two groups, this study and Hu K use propensity score matching to exclude the influence of confounding factors, and the results are consistent. In addition, compared with the Korean database, which lacks important demographic variables, such as FIGO staging, socioeconomic status and recurrence time and distribution, this database has a large sample size, detailed case data and survival outcomes. Therefore, our conclusion is more credible.

In summary, the OS and DFS of cervical AC/ASC after radical radiotherapy and chemotherapy were worse than those of SCC; in stage I-IIA2, there was no significant difference in 5-year survival time, but patients with AC/ASC were more likely to relapse; and the oncological outcome of radical radiotherapy and chemotherapy of cervical AC/ASC in more advanced stage IIB-IV disease was worse than that of SCC. Therefore, for patients with stage I-IIA2 cervical AC/ASC, the principle of clinical treatment can rely on that of SCC. For patients with stage IIB-IV cervical AC/ASC, individualized treatment should be carried out according to the different conditions of the patients, but not completely in accordance with the treatment principles of SCC. It has been reported that simultaneous radiotherapy and chemotherapy combined with neoadjuvant chemotherapy is a promising method to improve the survival rate of patients with cervical AC [24], and the application of targeted drugs may provide new opportunities for the treatment of patients with cervical AC. In the future, more large-scale, high-quality prospective studies are needed to study the prognostic differences and treatment between AC/ASC and SCC to improve the clinical prognosis of patients.

Our study has the following limitations. Firstly, we collected the case with the treatment of radiotherapy + chemotherapy which also called "sequential therapy" in China. Due to various reasons, such as inconsistent economic development, different hospital levels, different patient compliance, etc., we have no way to carry out standard concurrent chemoradiotherapy. Therefore, radiotherapy + chemotherapy has specific application in diagnosis and treatment in China and the inclusion of them can more objectively and accurately

Table 2 Data on stage I-IIA2 patients before and after matching

| Variables       | Unmatched SCC (n = 807) | AC/ASC (n = 41) | p-value | Matched SCC (n = 143) | AC/ASC (n = 38) | p-value |
|-----------------|-------------------------|-----------------|---------|-----------------------|-----------------|---------|
| Age (years)     | 56.25 ± 11.00           | 50.68 ± 13.27   | 0.002   | 53.94 ± 11.35         | 52.71 ± 11.36   | 0.556   |
| FIGO stage      |                         |                 |         |                       |                 |         |
| I               | 21 (2.6%)               | 1 (2.5%)        | 0.594   | 2 (1.4%)              | 1 (2.6%)        | 0.935   |
| II              | 8 (1.0%)                | 1 (2.5%)        |         | 2 (1.4%)              | 1 (2.6%)        |         |
| IIB1            | 101 (12.5%)             | 6 (14.6%)       |         | 17 (11.8%)            | 6 (15.8%)       |         |
| IIB2            | 79 (9.8%)               | 6 (14.6%)       |         | 19 (13.3%)            | 6 (15.8%)       |         |
| IIA             | 108 (13.4%)             | 3 (7.3%)        |         | 18 (12.6%)            | 3 (7.9%)        |         |
| IIA1            | 255 (31.6%)             | 10 (24.4%)      |         | 40 (28.0%)            | 9 (23.7%)       |         |
| IIA2            | 235 (29.1%)             | 14 (34.1)       |         | 45 (31.5%)            | 12 (31.6%)      |         |
| Tumour size     |                         |                 | 0.256   |                       |                 | 0.576   |
| > 4 cm          | 319 (39.5%)             | 21 (51.2%)      |         | 62 (43.3%)            | 20 (52.6%)      |         |
| ≤ 4 cm          | 325 (40.3%)             | 15 (36.6%)      |         | 56 (39.2%)            | 13 (34.2%)      |         |
| Unknown         | 163 (20.2%)             | 5 (12.2%)       |         | 25 (17.5%)            | 5 (13.2%)       |         |

FIGO International Federation of Gynecology and Obstetrics, SCC squamous cell carcinoma, AC/ASC adenocarcinoma/adenosquamous carcinoma.
Fig. 3 Survival curves before and after matching stage I to IV cervical cancer patients who met the study criteria. *Stage I to IIA2: before matching, panels A and B; after matching, panels C and D; Stage IIB to IV: before matching, panels E and F; after matching, panels G and H, SCC squamous cell carcinoma, AC/ASC adenocarcinoma/adenosquamous carcinoma
Table 3 Data on patients with stage IIIB-IV cervical cancer before and after matching

| Variables          | Unmatched       | Matched        | p-value |
|--------------------|-----------------|----------------|---------|
|                    | SCC (n = 4444)  | AC/ASC (n = 174) |         |
| Age (years)        | 55.67 ± 10.78   | 55.34 ± 10.66  | 0.694   |
| FIGO stage         |                 |                | 0.000   |
| IIB                | 1845 (41.5%)    | 67 (38.5%)     |         |
| III                | 34 (0.8%)       | 4 (2.3%)       |         |
| IIIA               | 228 (5.1%)      | 6 (3.5%)       |         |
| IIIB               | 2142 (48.2%)    | 78 (44.8%)     |         |
| IV                 | 61 (1.4%)       | 3 (1.7%)       |         |
| IVA                | 31 (0.7%)       | 4 (2.3%)       |         |
| IVB                | 103 (2.3%)      | 12 (6.9%)      |         |
| Tumour size        |                 | 0.557          |         |
| > 4 cm             | 2087 (47.0%)    | 75 (43.1%)     |         |
| ≤ 4 cm             | 1429 (32.1%)    | 62 (35.6%)     |         |
| Unknown            | 928 (20.9%)     | 37 (21.3%)     |         |
|                    | SCC (n = 690)   | AC/ASC (n = 173) |         |
|                    | 55.82 ± 11.24   | 55.49 ± 10.51  | 0.721   |
|FIGO International Federation of Gynecology and Obstetrics, SCC squamous cell carcinoma, AC/ASC adenosquamous carcinoma

reflect the diagnosis and treatment status of cervical cancer in China. Secondly, we performed stratification only for staging and did not compare the oncological outcomes of the two groups according to the treatment regimens. We plan to further explore to identify the optimal scheme in the future.

Abbreviations
SCC Squamous cell carcinoma; AC Adenocarcinoma carcinoma; ASC Adenosquamous carcinoma; OS Overall survival; DFS Disease-free survival; FIGO International Federation of Gynecology and Obstetrics; RWS Real-world study; PACS Picture archiving and communication system; RT Radiotherapy; CCRT Concurrent chemoradiotherapy.

Acknowledgements
We are grateful to Min Hao (Department of Obstetrics and Gynecology, The Second Hospital of Shanxi Medical University), Wuliang Wang (Department of Obstetrics and Gynecology, The Second Affiliated Hospital of Zhengzhou University), Ying Yang (Department of Obstetrics and Gynecology, Xinjiang Hospital, Army Medical University), Shan Kang (Department of Obstetrics and Gynecology, The Fourth Hospital of Hebei Medical University), Bin Ling (Department of Obstetrics and Gynecology, China-Japan Friendship Hospital), Xinli Sun and Hongwei Zhao (Department of Gynecology, Shanxi Cancer Hospital), Lizi Liang and Jihong Liu (Department of Gynecologic Oncology, Sun Yat-sen University Cancer Center), Yu Guo and Lihong Lin (Department of Gynecology, Anyang Tumor Hospital), Li Wang (Department of Gynecology, The Affiliated Tumor Hospital of Zhengzhou University), Weidong Zhao (Department of Gynecology and Oncology, Anhua County People's Hospital Cancer Hospital), Yan Ni (Department of Obstetrics and Gynecology, The Yuncheng Central Hospital of Shanxi Province), Donglin Li and Wentong Zhao (Department of Obstetrics and Gynecology, Guizhou Provincial People's Hospital), Jianxin Guo (Department of Obstetrics and Gynecology, Research Institute of Surgery, Daping Hospital, The Third Military Medical University), Xueqin Wang (Department of Obstetrics and Gynecology, The First Hospital of Guangzhou Medical University), Wuliang Wang (Department of Obstetrics and Gynecology, Shenzhen Hospital), Hongxin Pan (Department of Obstetrics and Gynecology, The Third Affiliated Hospital of Shenzhen University), Xiangdong Guo (Department of Obstetrics and Gynecology, The Second Hospital of Shandong University), Hongbing Wang (Department of Obstetrics and Gynecology, Lanzhou Maternity & Child Health Hospital), Weidong Zhao (Department of Obstetrics and Gynecology, No. 153, Center Hospital of the Liberation Army Hospital (Hospital No. 988 of the Chinese People's Liberation Army Joint Support Force)), Xiaohong Wang (Department of Obstetrics and Gynecology, Lanzhou Maternity & Child Health Hospital), Zhihua Liu (Department of Obstetrics and Gynecology, The Second Hospital of Shanxi Medical University), Anwei Lu (Department of Obstetrics and Gynecology, The Affiliated Tumor Hospital of Zhengzhou University), Yujie Zhai (Department of Obstetrics and Gynecology, The Affiliated Tumor Hospital of Lanzhou University), Qianyong Zhu (Department of Obstetrics and Gynecology, No. 153, Center Hospital of the Liberation Army Hospital (Hospital No. 988 of the Chinese People's Liberation Army Joint Support Force)), Xiaohong Wang (Department of Obstetrics and Gynecology, Shandong University), Lijing Li (Department of Obstetrics and Gynecology, Maternal and Child Health Care Hospital of Lanzhou) for providing medical records.

Authors’ contributions
Chunlin Chen is the corresponding authors. Ping Liu, Mei. J., Yanxiang Kong and Zhifeng Huo contributed equally to the work. PL: Methodology, Visualization, Writing original draft, Writing review and editing. MJ: Writing original draft, Writing review and editing. All authors read and approved the final manuscript.

Funding
The National Science and Technology Support Program of China (2014BAI05B03) The National Natural Science Fund of Guangdong (2015A030311024) The Science and Technology Plan of Guangzhou (158100075) The above funding sources provided financial assistance that had an important role in data collection.

Availability of data and material
The datasets used and/or analysed during the current study available from the corresponding author on reasonable request.
Declarations

Ethics approval and consent to participate
This study was approved and consent was obtained from the Ethic Committee of the Nanfang Hospital of Southern Medical University (approval number NEEC-2017–135 and clinical trial number ChiCTR1800017778; International Clinical Trials Registry Platform Search Port, http://apps.who.int/trialsearch/); registration date: August 14, 2018. Written informed consent to participate in the study was provided by all patients.

Consent for publication
Not Applicable.

Competing interests
The authors declare that they have no competing interests to disclose.

Author details
1Department of Obstetrics and Gynecology, Nanfang Hospital, Southern Medical University, Guangzhou 510515, China. 2Department of Obstetrics and Gynecology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China. 3Department of Reproductive Medicine, The Seventh Affiliated Hospital Sun Yat-Sen University, Shenzhen, China. 4Department of Obstetrics and Gynecology, Beijing Hospital, National Center of Gerontology, Beijing 100730, China. 5Foshan Maternal and Child Health Hospital, Foshan 528000, China. 6Department of Gynaecology, Liaoning Cancer Hospital, Liaoning Shenyang 110042, China. 7Department of Obstetrics and Gynecology, Xijing Hospital of Airforce Medical University, Xi’an, China. 8Department of Obstetrics and Gynecology, The Affiliated Hospital of Qingdao University, Qingdao 266016, China. 9Department of Obstetrics and Gynecology, Beijing 100730, China. 10Department of Gynaecology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China. 11Department of Obstetrics and Gynecology, Foshan Maternal and Child Health Hospital, Foshan 528000, China. 12Department of Gynaecology, Liaoning Cancer Hospital, Liaoning Shenyang 110042, China. 13Department of Obstetrics and Gynecology, Xijing Hospital of Airforce Medical University, Xi’an, China. 14Department of Obstetrics and Gynecology, Gansu Provincial Hospital, Lanzhou, China. 15Department of Gynaecology, The Affiliated Hospital of Qingdao University, Qingdao 266016, China. 16Department of Obstetrics and Gynecology, Xijing Hospital of Airforce Medical University, Xi’an, China. 17Department of Obstetrics and Gynecology, Peking Union Medical College, Beijing 100730, China.

Received: 15 July 2021 Accepted: 4 March 2022
Published online: 25 March 2022

References
1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2018. CA Cancer J Clin. 2018;68:7–30.
2. Watson M, Saraya M, Benard V, Coughlin SS, Flowers L, et al. Burden of cervical cancer in the United States, 1998–2003. Cancer. 2008;113:2855–64.
3. Koh WJ, Abu-Rustum NR, Bean S, Bradley K, Campos SM, Cho KR, Chen HS, Chu C, Clark R, Cohn D, et al. Cervical Cancer Version 3.2019, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2019;17(1):64–84.
4. Mabuchi S, Okazawa M, Matsuo K, Kawano M, Suzuki O, Miyatake T, Enomoto T, Kamiura S, Ogawa K, Kimura T. Impact of histological subtype on survival of patients with surgically treated stage II A2-IIIB cervical cancer: adenocarcinoma versus squamous cell carcinoma. GYNECOL ONCOL. 2012;127(1):114–20.
5. Yamauchi M, Fukuda T, Wada T, Kawanishi M, Imai K, Hashiguchi Y, Ichimura T, Yasui T. SUMI T: Comparison of outcomes between squamous cell carcinoma and adenocarcinoma in patients with surgically treated stage I-II cervical cancer. Mol Clin Oncol. 2014;2(4):518–24.
6. Jung EJ, Byun JM, Kim YN, Lee KB, Sung MS, Kim KT, Jeong DH. Cervical Adenocarcinoma Has a Poorer Prognosis and a Higher Propensity for Distant Recurrence Than Squamous Cell Carcinoma. INT J GYNECOL CANCER. 2017;27(6):1228–36.
7. Xie X, Song K, Cui B, Jiang J, Yang X, Kong B. A comparison of the prognosis between adenocarcinoma and squamous cell carcinoma in stage IB-IIC cervical cancer. INT J GYNECOL CANCER. 2018;28(3):522–31.
8. Wu SG, Sun JY, He ZY, Chen QH, Zhou J. Early-stage node negative cervical adenocarcinoma and squamous cell carcinoma show similar survival outcomes after hysterectomy: a population-based study. J GYNECOL ONCOL. 2017;28(6):e81.
9. Lee JY, Kim YT, Kim S, Lee B, Lim MC, Kim JW, Won YJ. Prognosis of Cervical Cancer in Patients with Concurrent Chemoradiation from National Database in Korea: A Comparison between Squamous Cell Carcinoma and Adenocarcinoma. PLOS ONE. 2015;10(12):e144887.
10. Huang YT, Wang CC, Tsai CS, Lai GH, Chang TC, Chu H, Hsieh S, Chen CK, Lee SP, Hong JH. Long-term outcome and prognostic factors for adenocarcinoma/adenosquamous carcinoma of cervix after definitive radiotherapy. Int J Radiat Oncol Biol. 2011;80(2):429–36.
11. Yokoi E, Mabuchi S, Takahashi R, Matsumoto Y, Kuroda H, Kozasa K, Kimura T. Impact of histological subtype on survival in patients with locally advanced cervical cancer that were treated with definitive radiotherapy: adenocarcinoma/adenosquamous carcinoma versus squamous cell carcinoma. J GYNECOL ONCOL. 2017;28(2):e19.
12. Hu K, Wang W, Liu X, Meng Q, Zhang F. Comparison of treatment outcomes between squamous cell carcinoma and adenocarcinoma of cervix after definitive radiotherapy or concurrent chemoradiotherapy. RADIAT ONCOL. 2018;13(1):249.
13. Rose PG, Javaheri OW, Stehman FB, Lanciano R, Thomas GM. Locally advanced adenocarcinoma and adenosquamous carcinomas of the cervix compared to squamous cell carcinomas of the cervix in Gynecologic Oncology Group trials of cisplatin-based chemoradiation. GYNECOL ONCOL. 2011;135(2):208–12.
14. Katanyoo K, Sanguunungsiinkul S, Mansurivitchaya S. Comparison of treatment outcomes between squamous cell carcinoma and adenocarcinoma in locally advanced cervical cancer. GYNECOL ONCOL. 2012;125(2):292–6.
15. Liu P, Lin L, Kong Y, Hsiao Z, Zhu L, Lin X, Lang J, Chen C. Comparison of survival outcomes between radio-chemotherapy and radical hysterectomy with postoperative standard therapy in patients with stage IB1 to IIA2 cervical cancer: long-term oncological outcome analysis in 37 Chinese hospitals. BMC Cancer. 2020;20(1):189.
16. Bhata N, Denny L. FIGO Cancer Report 2018. International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics. 2018;143(Suppl 2):2–3.
17. Pecorelli S, Zighi L, Ocicono F. Revised FIGO staging for carcinoma of the cervix. Int J Gynaecol Obstet. 2009;105(2):107–8.
18. Bhatla N, Aoki D, Sharma DN, Sankaranarayanan R. Cancer of the cervix uteri. Int J Gynaecol Obstet. 2015;131(Suppl 2):S88–95.
19. Bhata N, Aoki D, Sharma DN, Sankaranarayanan R. Cancer of the cervix uteri. Int J Gynaecol Obstet. 2018;143(Suppl 2):22–36.
20. Zhang W, Chen C, Liu P, Lu W, Mao M, Zhao W, Lu A, Ni Y. Impact of pelvic MRI in routine clinical practice on staging of IB1-IIB2 cervical cancer. Cancer Manag Res. 2019;11:3603–9.
21. Fujiiwa H, Yokota H, Bradley M, et al. Gynecologic Cancer InterGroup (GCIG) consensus review for cervical adenocarcinoma. Int J Gynecol Cancer 2014;24:596–101.
22. Sasieni P, Castanon A, Cuzick J. Screening and adenocarcinoma of the cervix. Int J Cancer. 2014;125(2):295–302.
23. Vinh-Hung V, Bourgain C, Vlastos G, Cserni G, De Ridder M, Storme G, Vlastos A. Prognostic value of histopathology and trends in cervical cancer: a SEER population study. BMC Cancer. 2007;7(1):164.
24. Tang J, Tang Y, Yang J, Huang S. Chemoradiation and adjuvant chemotherapy in advanced cervical adenocarcinoma. GYNECOL Oncol. 2012;125:297–302.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.